L-Glutamic acid-¹³C₅,¹⁵N

MedChemExpress

Cat. No.:	HY-14608S3			
CAS No.:	202468-31-3 O			
Molecular Formula:	$1_{3}C_{s}H_{g} = 1_{0}NO_{4}$ H_{2}			
Molecular Weight:	153.09 HO $13C$ $13C$ $13C$ $13C$			
Target:	Apoptosis; iGluR; Ferroptosis; Endogenous Metabolite; Isotope-Labeled Compounds $H_2 = H^{13}C_{-}^{-1}OH$			
Pathway:	Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic 15 NH ₂ Enzyme/Protease; Others			
Storage:	Powder -20°C 3 years 4°C 2 years			
	In solvent -80°C 6 months -20°C 1 month			

SOLVENT & SOLUBILITY

	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	6.5321 mL	32.6605 mL	65.3211 mL
		5 mM	1.3064 mL	6.5321 mL	13.0642 mL
		10 mM	0.6532 mL	3.2661 mL	6.5321 mL

BIOLOGICAL ACTIVITY				
Description	L-Glutamic acid- ¹³ C ₅ , ¹⁵ N is the ¹³ C- and ¹⁵ N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.			
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Product Data Sheet

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA